Answers are grounded in this paper and cite their sources.
expression is associated with adverse genetic risk, prior anthracycline exposure, and inferior OS, particularly in relapsed/refractory AML. These findings uncover a novel enhancer-mediated mechanism of ALDH1 induction in the context of anthracycline exposure and support the rationale for future clinical trials combining standard treatments with ALDH1-targeted approaches, including the clinical-stage inhibitor DIMATE.
No takes yet. Share an insight, caveat, or question.
Leonetti et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: